The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
The full article is available to subscribers Subscriber Login   

The FDA has approved an extended-release (ER) capsule formulation of amantadine (Gocovri – Adamas) for once-daily treatment of levodopa-induced dyskinesia in patients with Parkinson's disease (PD). It is the first product to be approved in the US for this indication. Immediate-release (IR) amantadine has been used off-label for years to manage levodopa-induced dyskinesia.

LEVODOPA-INDUCED DYSKINESIA — Levodopa combined with carbidopa is still the most effective treatment for symptoms of PD, but motor fluctuations and dyskinesia can be problematic as the disease progresses and higher levodopa doses are needed.1-3 Addition of a dopamine agonist, catechol O-methyltransferase (COMT) inhibitor, or monoamine oxidase type-B (MAO-B) inhibitor can reduce motor fluctuations, but may also increase the risk of dyskinesia. Amantadine can reduce levodopa-induced dyskinesia, and it ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
Article code: 5006a
 Electronic, downloadable article - $25